Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-10T10:17:34.759Z Has data issue: false hasContentIssue false
  • English
  • Français

Specific impact of stimulant, alcohol and cannabis use disorders on first-episode psychosis: 2-year functional and symptomatic outcomes

Published online by Cambridge University Press:  20 April 2017

C. Ouellet-Plamondon ,
A. Abdel-Baki ,
É. Salvat  and
S. Potvin
C. Ouellet-Plamondon
Affiliation:
Centre de recherche, Centre hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada Department of Psychiatry, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada
A. Abdel-Baki*
Affiliation:
Centre de recherche, Centre hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada Department of Psychiatry, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada
É. Salvat
Affiliation:
Centre de recherche, Centre hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada
S. Potvin
Affiliation:
Department of Psychiatry, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada Centre de recherche, Institut universitaire en santé mentale de Montréal (IUSMM), Montreal, Quebec, Canada
*
*Address for correspondence: A. Abdel-Baki, M.D., M.Sc., Centre de recherche, Centre hospitalier de l'Université de Montréal (CRCHUM), Montreal, Quebec, Canada and Department of Psychiatry, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada. (Email: amal.abdel-baki@umontreal.ca)
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Many studies have concluded that cannabis use disorder (CUD) negatively influences outcomes in first-episode psychosis (FEP). However, few have taken into account the impact of concurrent misuse of other substances.

Methods

This 2-year, prospective, longitudinal study of FEP patients, aged between 18 and 30 years, admitted to early intervention programs in Montreal, Quebec, Canada, examined the specific influence of different substance use disorders (SUD) (alcohol, cannabis, cocaine, amphetamines) on service utilization, symptomatic and functional outcomes in FEP.

Results

Drugs and alcohol were associated with lower functioning, but drugs had a greater negative impact on most measures at 2-year follow-up. Half of CUD patients and more than 65% of cocaine or amphetamine abusers presented polysubstance use disorder (poly-SUD). The only group that deteriorated from years 1 to 2 (symptoms and functioning) were patients with persistent CUD alone. Outcome was worse in CUD than in the no-SUD group at 2 years. Cocaine, amphetamines and poly-SUD were associated with worse symptomatic and functional outcomes from the 1st year of treatment, persisting over time with higher service utilization (hospitalization).

Conclusion

The negative impact attributed to CUD in previous studies could be partly attributed to methodological flaws, like including polysubstance abusers among cannabis misusers. However, our investigation confirmed the negative effect of CUD on outcome. Attention should be paid to persistent cannabis misusers, since their condition seems to worsen over time, and to cocaine and amphetamine misusers, in view of their poorer outcome early during follow-up and high service utilization.

Keywords

Amphetaminecannabiscocainefirst-episode psychosisfunctional outcomesymptomatic outcome
Type
Original Articles
Information
Psychological Medicine , Volume 47 , Issue 14 , October 2017 , pp. 2461 - 2471
Copyright
Copyright © Cambridge University Press 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Abdel-Baki, A, Ouellet-Plamondon, C, Salvat, E, Grar, K, Potvin, S (2017). Impact on symptomatic and functional outcome of substance use disorder persistence, 2-years after admission to a First Episode Psychosis program. Psychiatry Research 247, 113–119.CrossRefGoogle Scholar
Addington, D, Addington, J, Schissel, B (1990). A depression rating scale for schizophrenics. Schizophrenia Research 3, 247–251.CrossRefGoogle ScholarPubMed
Addington, J, Addington, D (2007). Patterns, predictors and impact of substance use in early psychosis: a longitudinal study. Acta Psychiatrica Scandinavica 115, 304–309.CrossRefGoogle ScholarPubMed
American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) , 4th edn, vol. 1. American Psychiatric Association: Arlington, VA.Google Scholar
Archie, S, Akhtar-Danesh, N, Norman, R, Malla, A, Roy, P, Zipursky, RB (2010). Ethnic diversity and pathways to care for a first episode of psychosis in Ontario. Schizophrenia Bulletin 36, 688–701.CrossRefGoogle ScholarPubMed
Archie, S, Gyomorey, K (2009). First episode psychosis, substance abuse and prognosis: a systematic review. Current Psychiatry Reviews 5, 153–163.CrossRefGoogle Scholar
Archie, S, Rush, BR, Akhtar-Danesh, N, Norman, R, Malla, A, Roy, P, Zipursky, RB (2007). Substance use and abuse in first-episode psychosis: prevalence before and after early intervention. Schizophrenia Bulletin 33, 1354–1363.CrossRefGoogle ScholarPubMed
Barak, Y, Baruch, Y, Achiron, A, Aizenberg, D (2008). Suicide attempts of schizophrenia patients: a case-controlled study in tertiary care. Journal of Psychiatric Research 42, 822–826.CrossRefGoogle ScholarPubMed
Barnett, JH, Werners, U, Secher, SM, Hill, KE, Brazil, R, Masson, K, Pernet, DE, Kirkbride, JB, Murray, GK, Bullmore, ET, Jones, PB (2007). Substance use in a population-based clinic sample of people with first-episode psychosis. The British Journal of Psychiatry 190, 515–520.CrossRefGoogle Scholar
Barrowclough, C, Gregg, L, Lobban, F, Bucci, S, Emsley, R (2015). The impact of cannabis use on clinical outcomes in recent onset psychosis. Schizophrenia Bulletin 41, 382–390.CrossRefGoogle ScholarPubMed
Bartels, SJ, Teague, GB, Drake, RE, Clark, RE, Bush, PW, Noordsy, DL (1993). Substance abuse in schizophrenia: service utilization and costs. Journal of Nervous and Mental Disease 181, 227–232.CrossRefGoogle Scholar
Carpenter, WT, Strauss, JS (1991). The prediction of outcome in schizophrenia. IV: eleven-year follow-up of the Washington IPSS cohort. Journal of Nervous and Mental Disease 179, 517–525.CrossRefGoogle ScholarPubMed
Ciompi, L (1980). Catamnestic long-term study on the course of life and aging of schizophrenics. Schizophrenia Bulletin 6, 606–618.CrossRefGoogle ScholarPubMed
Coldham, EL, Addington, J, Addington, D (2002). Medication adherence of individuals with a first episode of psychosis. Acta Psychiatrica Scandinavica 106, 286–290.CrossRefGoogle ScholarPubMed
Drake, R, Mueser, KT, McHugo, GJ (1996). Clinician rating scales: Alcohol Use Scale (AUS), Drug Use Scale (DUS), and Substance Abuse Treatment Scale (SATS). In Outcomes Assessment in Clinical Practice (ed. Sedered, L. and Dickey, B.), p. 301. Williams & Wilkins: Baltimore, MD.Google Scholar
Drake, RE, Mueser, KT (1996). Alcohol-use disorder and severe mental illness. Alcohol Research and Health 20, 87–93.Google ScholarPubMed
Faridi, K, Joober, R, Malla, A (2012). Medication adherence mediates the impact of sustained cannabis use on symptom levels in first-episode psychosis. Schizophrenia Research 141, 78–82.CrossRefGoogle ScholarPubMed
Fiorentini, A, Volonteri, LS, Dragogna, F, Rovera, C, Maffini, M, Mauri, MC, Altamura, CA (2011). Substance-induced psychoses: a critical review of the literature. Current Drug Abuse Reviews 4, 228–240.CrossRefGoogle ScholarPubMed
Foussias, G, Siddiqui, I, Fervaha, G, Agid, O, Remington, G (2015). Dissecting negative symptoms in schizophrenia: opportunities for translation into new treatments. Journal of Psychopharmacology 29, 116–126.CrossRefGoogle ScholarPubMed
Goldman, HH, Skodol, AE, Lave, TR (1992). Revising axis V for DSM-IV: a review of measures of social functioning. American Journal of Psychiatry 149, 1148–1156.Google ScholarPubMed
González-Pinto, A, Alberich, S, Barbeito, S, Gutierrez, M, Vega, P, Ibáñez, B, Haidar, MK, Vieta, E, Arango, C (2011). Cannabis and first-episode psychosis: different long-term outcomes depending on continued or discontinued use. Schizophrenia Bulletin 37, 631–639.CrossRefGoogle ScholarPubMed
Grech, A, Van Os, J, Jones, PB, Lewis, SW, Murray, RM (2005). Cannabis use and outcome of recent onset psychosis. European Psychiatry: The Journal of the Association of European Psychiatrists 20, 349–353.CrossRefGoogle ScholarPubMed
Guy, W (1976). ECDEU Assessment Manual for Psychopharmacology. U.S. Department of Health, Education, AND Welfare: Rockville, Maryland.Google Scholar
Haddad, P, Brain, C, Scott, J (2014). Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Related Outcome Measures 5, 43–62.CrossRefGoogle ScholarPubMed
Hall, RCW (1995). Global assessment of functioning: a modified scale. Psychosomatics 36, 267–275.CrossRefGoogle ScholarPubMed
Harrison, I, Joyce, EM, Mutsatsa, SH, Hutton, SB, Huddy, V, Kapasi, M, Barnes, TRE (2008). Naturalistic follow-up of co-morbid substance use in schizophrenia: the West London first-episode study. Psychological Medicine 38, 79–88.CrossRefGoogle ScholarPubMed
Haywood, TW, Kravitz, HM, Grossman, LS, Cavanaugh, JL, Davis, JM, Lewis, DA (1995). Predicting the ‘revolving door’ phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. The American Journal of Psychiatry 152, 856–861.Google ScholarPubMed
Heinrichs, DW, Hanlon, TE, Carpenter, WT (1984). The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 10, 388–398.CrossRefGoogle ScholarPubMed
Kay, SR, Flszbein, A, Opfer, LA (1987). The positive and negative syndrome scale (PANSS) for Schizophrenia. Schizophrenia Bulletin 13, 261–276.CrossRefGoogle ScholarPubMed
Koskinen, J, Löhönen, J, Koponen, H, Isohanni, M, Miettunen, J (2009). Prevalence of alcohol use disorders in schizophrenia–a systematic review and meta-analysis. Acta Psychiatrica Scandinavica 120, 85–96.CrossRefGoogle ScholarPubMed
Koskinen, J, Löhönen, J, Koponen, H, Isohanni, M, Miettunen, J (2010). Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophrenia Bulletin 36, 1115–1130.CrossRefGoogle ScholarPubMed
Lambert, M, Conus, P, Lubman, DI, Wade, D, Yuen, H, Moritz, S, Naber, D, McGorry, PD, Schimmelmann, BG (2005). The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatrica Scandinavica 112, 141–148.CrossRefGoogle ScholarPubMed
Large, M, Mullin, K, Gupta, P, Harris, A, Nielssen, O (2014). Systematic meta-analysis of outcomes associated with psychosis and co-morbid substance use. The Australian and New Zealand Journal of Psychiatry 48, 418–432.CrossRefGoogle ScholarPubMed
Larsen, TK, Melle, I, Auestad, B, Friis, S, Haahr, U, Johannessen, JO, Opjordsmoen, S, Rund, BR, Simonsen, E, Vaglum, P, McGlashan, TH (2006). Substance abuse in first-episode non-affective psychosis. Schizophrenia Research 88, 55–62.CrossRefGoogle ScholarPubMed
Levy, E, Pawliuk, N, Joober, R, Abadi, S, Malla, A (2012). Medication-adherent first-episode psychosis patients also relapse: why? Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie 57, 78–84.CrossRefGoogle ScholarPubMed
Linszen, DH, Dingemans, PM, Lenior, ME (1994). Cannabis abuse and the course of recent-onset schizophrenic disorders. Archives of General Psychiatry 51, 273–279.CrossRefGoogle ScholarPubMed
Malla, A, Norman, R, Bechard-Evans, L, Schmitz, N, Manchanda, R, Cassidy, C (2008). Factors influencing relapse during a 2-year follow-up of first-episode psychosis in a specialized early intervention service. Psychological Medicine 38, 1585–1593.CrossRefGoogle Scholar
Mazzoncini, R, Donoghue, K, Hart, J, Morgan, C, Doody, GA, Dazzan, P, Jones, PB, Morgan, K, Murray, RM, Fearon, P (2010). Illicit substance use and its correlates in first episode psychosis. Acta Psychiatrica Scandinavica 121, 351–358.CrossRefGoogle ScholarPubMed
McLean, D, Gladman, B, Mowry, B (2012). Significant relationship between lifetime alcohol use disorders and suicide attempts in an Australian schizophrenia sample. The Australian and New Zealand Journal of Psychiatry 46, 132–140.CrossRefGoogle Scholar
Murray, RM, Paparelli, A, Morrison, PD, Marconi, A, Di Forti, M (2013). What can we learn about schizophrenia from studying the human model, drug-induced psychosis? American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 162B, 661–670.CrossRefGoogle ScholarPubMed
Nicole, L, Abdel-Baki, A, Lesage, A, Granger, B, Stip, E, Lalonde, P (2007). Study of the follow-up of early psychosis at the Université de Montréal (L'Etude de Suivi des Psychoses Emergentes de l'Université de Montréal (ESPEUM): context, objectives and methodology. Santé Mentale Au Québec 32, 317–331.CrossRefGoogle ScholarPubMed
Norman, RMG, Manchanda, R, Malla, AK, Windell, D, Harricharan, R, Northcott, S (2011). Symptom and functional outcomes for a 5 year early intervention program for psychoses. Schizophrenia Research 129, 111–115.CrossRefGoogle ScholarPubMed
Early Psychosis Guidelines Writing Group and EPPIC National Support Program (2016). Australian Clinical Guidelines for Early Psychosis, 2nd edn, 2016, Orygen, The National Centre of Excellence in Youth Mental Health, Melbourne.Google Scholar
Ouellet-Plamondon, C, Abdel-Baki, A (2011). Young urban adults suffering from psychosis: the importance of close team work. Santé Mentale Au Québec 36, 33–51.CrossRefGoogle ScholarPubMed
Owen, RR, Fischer, EP, Booth, BM, Cuffel, BJ (1996). Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatric Services 47, 853–858.Google ScholarPubMed
Rebgetz, S, Conus, P, Hides, L, Kavanagh, DJ, Cotton, S, Schimmelmann, BG, McGorry, PD, Lambert, M (2014). Predictors of substance use reduction in an epidemiological first-episode psychosis cohort. Early Intervention in Psychiatry 8, 358–365.CrossRefGoogle Scholar
Roy, MA, Lanctôt, G, Mérette, C, Cliche, D, Fournier, JP, Boutin, P, Rodrigue, C, Charron, L, Turgeon, M, Hamel, M, Montgrain, N, Nicole, L, Pirès, A, Wallot, H, Ponton, AM, Garneau, Y, Dion, C, Lavallée, JC, Potvin, A, Szatmari, P, Maziade, M (1997). Clinical and methodological factors related to reliability of the best-estimate diagnostic procedure. The American Journal of Psychiatry 154, 1726–1733.CrossRefGoogle ScholarPubMed
Rubio, G, Martínez, I, Ponce, G, Jiménez-Arriero, MA, López-Muñoz, F, Alamo, C (2006). Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie 51, 531–539.CrossRefGoogle ScholarPubMed
Sara, GE, Large, MM, Matheson, SL, Burgess, PM, Malhi, GS, Whiteford, HA, Hall, WD (2015). Stimulant use disorders in people with psychosis: a meta-analysis of rate and factors affecting variation. The Australian and New Zealand Journal of Psychiatry 49, 106–117.CrossRefGoogle ScholarPubMed
Schoeler, T, Monk, A, Sami, MB, Klamerus, E, Foglia, E, Brown, R, Camuri, G, Altamura, AC, Murray, R, Bhattacharyya, S (2016). Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. The Lancet. Psychiatry 3, 215–225.CrossRefGoogle ScholarPubMed
Serper, MR, Chou, JC, Allen, MH, Czobor, P, Cancro, R (1999). Symptomatic overlap of cocaine intoxication and acute schizophrenia at emergency presentation. Schizophrenia Bulletin 25, 387–394.CrossRefGoogle ScholarPubMed
Sevy, S, Kay, SR, Opler, LA, van Praag, HM (1990). Significance of cocaine history in schizophrenia. The Journal of Nervous and Mental Disease 178, 642–648.CrossRefGoogle ScholarPubMed
Sönmez, N, Røssberg, JI, Evensen, J, Barder, HE, Haahr, U, Ten Velden Hegelstad, W, Joa, I, Johannessen, JO, Langeveld, H, Larsen, TK, Melle, I, Opjordsmoen, S, Rund, BR, Simonsen, E, Vaglum, P, McGlashan, T, Friis, S (2016). Depressive symptoms in first-episode psychosis: a 10-year follow-up study. Early Intervention in Psychiatry 10, 227–233.CrossRefGoogle ScholarPubMed
Sorbara, F, Liraud, F, Assens, F, Abalan, F, Verdoux, H (2003). Substance use and the course of early psychosis: a 2-year follow-up of first-admitted subjects. European Psychiatry: The Journal of the Association of European Psychiatrists 18, 133–136.CrossRefGoogle ScholarPubMed
Swartz, MS, Wagner, HR, Swanson, JW, Stroup, TS, McEvoy, JP, Canive, JM, Miller, DD, Reimherr, F, McGee, M, Khan, A, Van Dorn, R, Rosenheck, RA, Lieberman, JA (2006). Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. The Journal of Nervous and Mental Disease 194, 164–172.CrossRefGoogle ScholarPubMed
Turkington, A, Mulholland, CC, Rushe, TM, Anderson, R, McCaul, R, Barrett, SL, Barr, RS, Cooper, SJ (2009). Impact of persistent substance misuse on 1-year outcome in first-episode psychosis. The British Journal of Psychiatry 195, 242–248.CrossRefGoogle ScholarPubMed
Velligan, DI, Weiden, PJ, Sajatovic, M, Scott, J, Carpenter, D, Ross, R, Docherty, JP, Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness (2009). The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. The Journal of Clinical Psychiatry 70 (Suppl 4), 1–46; quiz 47–48.Google ScholarPubMed
Wade, D, Harrigan, S, Edwards, J, Burgess, PM, Whelan, G, McGorry, PD (2005). Patterns and predictors of substance use disorders and daily tobacco use in first-episode psychosis. The Australian and New Zealand Journal of Psychiatry 39, 892–898.Google ScholarPubMed
Wade, D, Harrigan, S, Edwards, J, Burgess, PM, Whelan, G, McGorry, PD (2006). Substance misuse in first-episode psychosis: 15-month prospective follow-up study. The British Journal of Psychiatry: The Journal of Mental Science 189, 229–234.CrossRefGoogle ScholarPubMed
Zammit, S, Moore, THM, Lingford-Hughes, A, Barnes, TRE, Jones, PB, Burke, M, Lewis, G (2008). Effects of cannabis use on outcomes of psychotic disorders: systematic review. The British Journal of Psychiatry 193, 357–363.CrossRefGoogle ScholarPubMed
Zhornitsky, S, Stip, E (2012). Oral versus long-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment nonadherence: a systematic review. Schizophrenia Research and Treatment 2012, 407171.Google ScholarPubMed
Zhornitsky, S, Stip, E, Pampoulova, T, Rizkallah, E, Lipp, O, Bentaleb, LA, Chiasson, J-P, Potvin, S (2010). Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia. Movement Disordersy 25, 2188–2194.CrossRefGoogle ScholarPubMed
Supplementary material: File

Ouellet-Plamondon supplementary material

Ouellet-Plamondon supplementary material

Download Ouellet-Plamondon supplementary material(File)
File 18 KB